Clinical trials: Glioma Tumor Recurrence
Malignant Glioma, Glioblastoma Multiforme
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL13-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00041587
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Glioblastoma
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability, and preliminary efficacy of TX103-CAR-T Cell Injection, a B7-H3-targeting chimeric antigen receptor T-cell (CAR-T)…
- Trial name
- NCT05241392
- Testing
- B7-H3-targeting CAR-T cells/TX103-CAR-T Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma, Brain Tumor
Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma
The purpose of this research study is to determine if sunitinib can get past the blood-brain barrier and into the brain tumor. Sunitinib has shown promising results in treating other cancers and works by blocking blood flow to…
- Trial name
- NCT00864864
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma Multiforme
A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia
This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy.
- Trial name
- NCT02507102
- Testing
- Voyager
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- Nativis, Inc.
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Glioblastoma, Glioblastoma Multiforme
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
This research is being done to test if it is safe to give nivolumab with targeted immunotherapy drugs for recurrent glioblastoma (GBM), a type of brain tumor.
- Trial name
- NCT03707457
- Testing
- Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Cancer
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
Glioblastoma, the most prevalent malignant tumor in the central nervous system, is characterized by high invasiveness and a propensity to recur, contributing to a relatively elevated mortality rate.
- Conditions
- Glioblastoma, Cancer, Temozolomide
- Trial name
- NCT06279767
- Testing
- 6-mercaptopurine
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or…
- Trial name
- NCT00003241
- Testing
- phenylacetate
- Where
- 6 sites in United States
- Sponsor
- Texas Children's Cancer Center
Glioblastoma
Glioblastoma Response Prediction to Apatinib
Anti-angiogenic therapy is an important treatment strategy for recurrent glioblastoma. Our previous study provided evidence for a potential benefit of apatinib, a humanized monoclonal antibody against VEGFR-2, when added to…
- Trial name
- NCT04814329
- Testing
- genetic characteristic
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Sanbo Brain Hospital
Glioma
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for…
- Trial name
- NCT07778979
- Testing
- [18F]FMISO-PET with contrast-enhanced MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
3T MRI Biomarkers of Glioma Treatment Response
This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01996527
- Testing
- 3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent or Refractory Pediatric Ependymoma
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
- Trial name
- PETEY (NCT01032070)
- Testing
- erlotinib, etoposide
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 25 people
- Sponsor
- OSI Pharmaceuticals
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
Clinical Part: The objective of this study is to determine the efficacy and safety of SUTENT in patients with recurrent or progressive glioblastoma multiforme.Patients with tissue based diagnosis of intracranial glioblastoma…
- Trial name
- SURGE01-07 (NCT00535379)
- Testing
- Sunitinib
- Where
- 10 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- Medical University Innsbruck
Solid Tumor, Glioblastoma
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma…
- Conditions
- Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Trial name
- NCT05095441
- Testing
- C5252
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- ImmVira Pharma Co. Ltd
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Phase I Part: To determine the maximum tolerated dose (MTD) and pharmacokinetics of BIBW 2992 administered in combination with TMZ in patients with recurrent malignant gliomas (WHO Grade III and IV).
- Trial name
- NCT00727506
- Testing
- BIBW 2992, TMZ, BIBW 2992 plus TMZ
- Where
- 28 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.